@article{pal_renal_2015,
	title = {Renal cell carcinoma: {An} update for the practicing urologist},
	volume = {2},
	issn = {2214-3882},
	url = {://WOS:000215388000003},
	doi = {10.1016/j.ajur.2015.04.012},
	abstract = {Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) now representing a standard of care. The present paper is to review the current status of relevant clinical trials that were either recently completed or ongoing. (1) Though observation remains a standard of care following resection of localized disease, multiple trials are underway to assess VEGF-and mTOR-directed therapies in this setting. (2) While the preponderance of retrospective data favors cytoreductive nephrectomy in the context of targeted agents, prospective data to support this approach is still forthcoming. (3) The first-line management of mRCC may change substantially with multiple studies exploring vaccines, immune checkpoint inhibitors, and novel targeted agents currently underway. In general, prospective studies that will report within the next several years will be critical in defining the role of adjuvant therapy and cytoreductive nephrectomy. Over the same span of time, the current treatment paradigm for first-line therapy may evolve. (C) 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier (Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license.},
	language = {English},
	number = {1},
	journal = {Asian Journal of Urology},
	author = {Pal, S. K. and Bergerot, P. and Figlin, R. A.},
	month = jan,
	year = {2015},
	keywords = {Cabozantinib, Cytoreductive nephrectomy, Immunotherapy, PD-1, Renal cell carcinoma, Sdjuvant therapy, Urology \& Nephrology, Vaccines, adjuvant, cancer, carbonic-anhydrase ix, cytoreductive nephrectomy, interferon-alpha, pazopanib, phase-iii, sorafenib, survival, targeted-therapy},
	pages = {19--25},
}

{"_id":"GSJez9YGQNiEyCegJ","bibbaseid":"pal-bergerot-figlin-renalcellcarcinomaanupdateforthepracticingurologist-2015","authorIDs":[],"author_short":["Pal, S. K.","Bergerot, P.","Figlin, R. A."],"bibdata":{"bibtype":"article","type":"article","title":"Renal cell carcinoma: An update for the practicing urologist","volume":"2","issn":"2214-3882","url":"://WOS:000215388000003","doi":"10.1016/j.ajur.2015.04.012","abstract":"Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) now representing a standard of care. The present paper is to review the current status of relevant clinical trials that were either recently completed or ongoing. (1) Though observation remains a standard of care following resection of localized disease, multiple trials are underway to assess VEGF-and mTOR-directed therapies in this setting. (2) While the preponderance of retrospective data favors cytoreductive nephrectomy in the context of targeted agents, prospective data to support this approach is still forthcoming. (3) The first-line management of mRCC may change substantially with multiple studies exploring vaccines, immune checkpoint inhibitors, and novel targeted agents currently underway. In general, prospective studies that will report within the next several years will be critical in defining the role of adjuvant therapy and cytoreductive nephrectomy. Over the same span of time, the current treatment paradigm for first-line therapy may evolve. (C) 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier (Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license.","language":"English","number":"1","journal":"Asian Journal of Urology","author":[{"propositions":[],"lastnames":["Pal"],"firstnames":["S.","K."],"suffixes":[]},{"propositions":[],"lastnames":["Bergerot"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Figlin"],"firstnames":["R.","A."],"suffixes":[]}],"month":"January","year":"2015","keywords":"Cabozantinib, Cytoreductive nephrectomy, Immunotherapy, PD-1, Renal cell carcinoma, Sdjuvant therapy, Urology & Nephrology, Vaccines, adjuvant, cancer, carbonic-anhydrase ix, cytoreductive nephrectomy, interferon-alpha, pazopanib, phase-iii, sorafenib, survival, targeted-therapy","pages":"19–25","bibtex":"@article{pal_renal_2015,\n\ttitle = {Renal cell carcinoma: {An} update for the practicing urologist},\n\tvolume = {2},\n\tissn = {2214-3882},\n\turl = {://WOS:000215388000003},\n\tdoi = {10.1016/j.ajur.2015.04.012},\n\tabstract = {Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) now representing a standard of care. The present paper is to review the current status of relevant clinical trials that were either recently completed or ongoing. (1) Though observation remains a standard of care following resection of localized disease, multiple trials are underway to assess VEGF-and mTOR-directed therapies in this setting. (2) While the preponderance of retrospective data favors cytoreductive nephrectomy in the context of targeted agents, prospective data to support this approach is still forthcoming. (3) The first-line management of mRCC may change substantially with multiple studies exploring vaccines, immune checkpoint inhibitors, and novel targeted agents currently underway. In general, prospective studies that will report within the next several years will be critical in defining the role of adjuvant therapy and cytoreductive nephrectomy. Over the same span of time, the current treatment paradigm for first-line therapy may evolve. (C) 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier (Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license.},\n\tlanguage = {English},\n\tnumber = {1},\n\tjournal = {Asian Journal of Urology},\n\tauthor = {Pal, S. K. and Bergerot, P. and Figlin, R. A.},\n\tmonth = jan,\n\tyear = {2015},\n\tkeywords = {Cabozantinib, Cytoreductive nephrectomy, Immunotherapy, PD-1, Renal cell carcinoma, Sdjuvant therapy, Urology \\& Nephrology, Vaccines, adjuvant, cancer, carbonic-anhydrase ix, cytoreductive nephrectomy, interferon-alpha, pazopanib, phase-iii, sorafenib, survival, targeted-therapy},\n\tpages = {19--25},\n}\n\n","author_short":["Pal, S. K.","Bergerot, P.","Figlin, R. A."],"key":"pal_renal_2015","id":"pal_renal_2015","bibbaseid":"pal-bergerot-figlin-renalcellcarcinomaanupdateforthepracticingurologist-2015","role":"author","urls":{"Paper":"https://bibbase.org/zotero/://WOS:000215388000003"},"keyword":["Cabozantinib","Cytoreductive nephrectomy","Immunotherapy","PD-1","Renal cell carcinoma","Sdjuvant therapy","Urology & Nephrology","Vaccines","adjuvant","cancer","carbonic-anhydrase ix","cytoreductive nephrectomy","interferon-alpha","pazopanib","phase-iii","sorafenib","survival","targeted-therapy"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/vincentwntu","creationDate":"2020-01-26T03:06:33.840Z","downloads":0,"keywords":["cabozantinib","cytoreductive nephrectomy","immunotherapy","pd-1","renal cell carcinoma","sdjuvant therapy","urology & nephrology","vaccines","adjuvant","cancer","carbonic-anhydrase ix","cytoreductive nephrectomy","interferon-alpha","pazopanib","phase-iii","sorafenib","survival","targeted-therapy"],"search_terms":["renal","cell","carcinoma","update","practicing","urologist","pal","bergerot","figlin"],"title":"Renal cell carcinoma: An update for the practicing urologist","year":2015,"dataSources":["icTw8KRRMMANXJHRd"]}